Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
18,214 total articles
Ceribell, Inc. announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) for the Ceribell Delirium Monitor System, enabling up to $2,171 additional reimbursement per eligible Medicare patient. This follows FDA clearance of the device and supports faster, objective delirium screening in…
Ocular Therapeutix announced positive results from its SOL-1 Phase 3 trial supporting a planned NDA submission for AXPAXLI in wet AMD in Q4 2026, based on efficacy, safety, and confirmatory evidence. The company expects accelerated FDA review via the 505(b)(2) pathway and is advancing clinical development for wet AMD and diabetic retinal disease. S…
Tonix Pharmaceuticals announced positive feedback from a Type C FDA meeting regarding the design of their adaptive Phase 2 field study of TNX-4800, a long-acting human monoclonal antibody aimed at preventing Lyme disease in adults. The study is slated to start in Q1 2027 and will assess both efficacy and safety over a 52-week period, with TNX-4800 …
Liberty Global has finalized the purchase of Vodafone Group's 50% stake in VodafoneZiggo, consolidating ownership to form Ziggo Group, which serves 13 million customers in the Benelux region. The company plans to spin off and list Ziggo Group on the Amsterdam stock exchange in 2027. This move follows Liberty Global's strategy to unlock value in its…
Aurora Mobile Limited has announced the launch of LoopAgent, a production-grade execution engine within its GPTBots.ai AI agent platform. LoopAgent enables autonomous handling of complex, multi-step business tasks, offering enterprises enhanced control, security, and auditing capabilities. This development marks a shift towards AI agents that can c…
TG Therapeutics reported second quarter 2026 total global revenue of approximately $240 million, driven primarily by BRIUMVI U.S. net product revenue of $228 million, representing a 64% year-over-year increase. The company raised its full-year 2026 global revenue guidance to approximately $950 million, including $890-$905 million for BRIUMVI in the…
Plug Power Inc., a pioneer in hydrogen fuel cell technology and integrated hydrogen solutions, announced it will report its second quarter 2026 financial results on August 10, 2026. The company is a leader in hydrogen production, storage, and fueling infrastructure and supports major global corporations. The results call and webcast details accompa…
Sportradar Group AG posted a 19% increase in revenue for Q2 2026 to €378 million, driven by growth in Betting Technology & Solutions and Sports Content services. Adjusted EBITDA also rose 19% to €76 million with margin expansion. The company expanded its market presence via multi-year partnerships with prediction market platforms Kalshi and Polymar…
BCB Bancorp, Inc. (NASDAQ: BCBP) reported a net loss of $14.8 million for the second quarter of 2026, a significant deterioration from net income in both the previous quarter and prior year. The loss was driven by a $19 million provision for credit losses, a $5.3 million goodwill impairment, and a $2.6 million loss on loan sales. The company announ…
Eva Live Inc. announces the creation of Eva Defense Inc.'s advisory board with the appointments of General Robert Brooks Brown and Ross Mandel. This step initiates Eva Live's expansion into the defense sector, leveraging its AI technology to develop integrated military-grade products such as autonomous drones, command consoles, and resilient commun…
Lantronix Inc., an Edge AI and Industrial IoT solutions provider, announced that its CEO and CFO will participate in upcoming investor conferences hosted by Canaccord Genuity and Needham. These engagements include a fireside chat and multiple one-on-one meetings aimed at discussing the company's growth and strategic initiatives in high-growth techn…
Adlai Nortye Ltd., a clinical-stage biotech company, announced the submission of Clinical Trial Notification to Australia's regulatory body and approval from the Human Research Ethics Committee to begin a global Phase I trial of AN4035, a first-in-class antibody drug conjugate (ADC) targeting CEACAM5 with a pan-RAS(ON) inhibitor payload. The trial …
Can-Fite BioPharma has submitted a Phase 2 clinical trial protocol for Piclidenoson to treat Lowe syndrome, a rare genetic disease with no approved treatments. This open-label, single-center study will evaluate safety and efficacy in 5 adult patients, focusing on kidney function improvement. The drug is already in Phase 3 trials for psoriasis and h…
Opus Genetics has completed patient enrollment in its registrational Phase 3 trial of OPGx-LCA5, an investigational gene therapy for LCA5-associated inherited retinal disease. The trial design aligns with FDA Rare Disease Evidence Principles, aiming for a Biologics License Application submission based on six-month efficacy data expected by the end …
Douglas Dynamics, Inc. (NYSE: PLOW) announced record second quarter 2026 financial results with net sales increasing 10% to $214.6 million and adjusted EBITDA rising 5% to a record $44.6 million. The company reported adjusted diluted EPS growth of 7% to $1.22 and returned $10 million in cash to shareholders. Strong snowfall led to robust preseason …
Eton Pharmaceuticals will report its second quarter 2026 financial results on August 13, 2026, followed by a management conference call and webcast. The company focuses on developing and commercializing treatments for rare diseases and currently markets eleven rare disease products, with several additional candidates in late-stage development.
Brookfield Asset Management has finalized its acquisition of Oaktree, enhancing its credit investing capabilities and expanding its global reach. The merger strengthens Brookfield's credit business across multiple credit strategies and solidifies the U.S. as its largest market, accounting for over 60% of employees and nearly half of revenue.
Supernus Pharmaceuticals delivered a 32% increase in total revenues to $219.1 million for Q2 2026, driven by strong sales growth of its CNS-focused products including Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO. Collaboration revenue with Biogen on ZURZUVAE further boosted results. The company raised its full-year 2026 revenue guidance and announced an …
Integer Holdings Corporation reported a slight decline in organic sales and operating income in Q2 2026 compared to Q2 2025 but delivered stable adjusted net income and a small increase in adjusted EPS. The company also disclosed a definitive agreement for an all-cash acquisition by KKR valuing Integer at $5.7 billion, with stockholders to receive …
Indivior Pharmaceuticals delivered robust second quarter 2026 financial results, highlighted by a 14% year-over-year increase in total net revenue to $343 million and 21% growth in flagship SUBLOCADE net revenue. Record GAAP and non-GAAP net incomes and a 111% rise in adjusted EBITDA from the prior year underscore operational strength. The company …
Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to merge in a tax-free all-stock transaction to create a large CNS-focused biopharmaceutical company expected to generate $2.2 billion in combined annual revenue and $125 million in annual cost synergies. The combined entity will operate under the name Supernus, Inc. with Jack Khatta…
Integer Holdings Corporation, a leading global medical device contract manufacturer, has agreed to be acquired by private equity firm KKR in a $5.7 billion all-cash transaction. Shareholders will receive $127 per share, representing a 51.8% premium over the pre-review price. The deal follows a strategic review and aims to provide Integer with capit…
Diginex Limited announced it has obtained $70 million in private funding commitments to finance its proposed acquisition of Resulticks and has extended the acquisition long-stop date to August 12, 2026. The transaction remains subject to customary conditions and approvals, with no guarantee of completion.
Parsons Corporation has been selected as the lead designer for the Interstate 526 Long Point Road Interchange Improvements project in South Carolina. As part of the Ames Construction design-build team, Parsons will provide engineering and design services to enhance safety, reduce congestion, and improve mobility in Charleston's busy transportation …
CNH Industrial reported Q2 2026 revenues of $4.8 billion, a 2% increase year-over-year, but net income declined to $141 million from $217 million in Q2 2025. Adjusted net income decreased 25% to $161 million. The company noted continued pressure on farmer economics amid a trough in the agriculture cycle, but positive signs in equipment cycles. Desp…
